Press Release

PhRMA’s Steve Ubl Says White House Drug Pricing Proposal “Not a Serious Plan” to Lower What Patients Pay

WASHINGTON, D.C. (September 9, 2021) – Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl made the following statement in response to the administration’s drug pricing plan:

“What was released today is a laundry list of old partisan ideas and not a serious plan to address what patients pay out of pocket for prescription drugs. What it leaves out is any attempt to fix a broken insurance system that discriminates against sick patients and does nothing to hold insurers and middlemen accountable for pocketing savings from our companies that should go to patients to lower their costs.
 
“It’s hard to ignore the irony that this is being released the same day the White House is unveiling a separate plan meant to regain control of the Covid-19 pandemic. The biopharmaceutical industry is continuing to work around the clock against this pandemic while this same White House is trying to make it more difficult for our industry to continue the fight against this pandemic and plan for future health crises.” 

 

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $1 trillion in the search for new treatments and cures, including $91.1 billion in 2020 alone.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:

www.PhRMA.org 
www.Innovation.org 
www.MAT.org
www.Facebook.com/PhRMA 
www.Twitter.com/PhRMA